Wings Therapeutics

2600 Tenth Street, #435

Berkeley

Established 2019

Wings Therapeutics is a company dedicated to the development of transformational therapies for patients that suffer from Dystrophic Epidermolysis Bullosa (DEB). The company was founded in 2019 by EB Research partnership and ProQR Therapeutics to continue development of a pipeline of potential RNA therapies for several forms of DEB in a focussed organization.
Wings Therapeutics is currently conducting a Phase 1/2 clinical trial for QR-313 in patients that suffer from DEB due to mutations in exon 73.